Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
Tailored therapies
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
Learn more: Miniature testing of drug pairs on tumour biopsies
The Latest on: Personalized medicine
[google_news title=”” keyword=”personalized medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized medicine
- Artificial Intelligence is medicine's next frontier. Israel is leading the wayon May 18, 2024 at 7:08 am
Opinion: As we celebrate 76 years of Israeli healthcare innovation we are excited by the AI-based projects being undertaken in Israel.
- Personalized Medicine Biomarkers Market Size and Trends 2024- Exploring Projected Growth at 16.3% CAGRon May 15, 2024 at 5:00 pm
Marketresearch.biz reports that the The global Personalized Medicine Biomarkers Market was valued at USD 15.5 Billion in 2022. It is expected to reach USD 67.6 Billion by 2032, with a CAGR of 16.3% ...
- Tumor tissue on a chip: New possibilities for cell therapies and personalized medicineon May 15, 2024 at 9:35 am
The researchers have now published their development in the journal Cell Stem Cell. This observation was made using tumor-on-chip technology: In this case a complex in vitro system of a breast cancer ...
- Epic to add data tool for personalized medicineon May 15, 2024 at 7:08 am
Epic plans to launch a new personalized care data tool this summer, according to Wis Business News.
- An easy pill to swallow—new 3D printing research paves way for personalized medicationon May 14, 2024 at 8:45 am
A new technique for 3D printing medication has enabled the printing of multiple drugs in a single tablet, paving the way for personalized pills that can deliver timed doses.
- Medical ‘Digital Twins’ Will Lead the Way to Personalized Medicineon May 14, 2024 at 6:13 am
It promises to speed up a long-envisioned era of personalized medicine, which uses targeted interventions customized to each patient, to maintain or restore health. At the heart of a digital twin is a ...
- How precision and personalized medicine M&A performed in the medical devices industry in Q1 2024on May 13, 2024 at 7:41 pm
Analysis of the key themes driving M&A activity reveals that precision and personalized medicine accounted for 2 medical devices deals announced in Q1 2024, worth a total value of $943.9m. The $943.9m ...
- How personalized medicine is transforming your health careon May 10, 2024 at 1:42 am
As it happened, he is a co-leader of a study at the cutting edge of what’s come to be called precision, or personalized, medicine. The approach, built on advances in gene research and data ...
- The Role of Data Science in Revolutionizing Personalized Medicine and Drug Discoveryon May 9, 2024 at 1:49 am
Genomic data holds immense promise in personalized medicine. Advances in DNA sequencing technologies have made it possible to decode an individual's entire genome, uncovering genetic variations that ...
via Bing News